Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Mucosal Immunol ; 6(6): 1191-201, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23549449

RESUMO

CD30 ligand (CD30L, CD153), a member of the tumor necrosis factor (TNF) superfamily, and its receptor CD30 are important for differentiation and activation of CD4(+) T helper type 17 (Th17) cells. In this report, we demonstrate that the interleukin 17A (IL-17A)-producing γδ T cells normally developed in the fetal thymus, whereas Vγ1(-)Vγ4(-) γδ T cells expressed Vγ6/Vδ1 gene transcript selectively decreased in mucosa-associated tissues in naive CD30KO or CD30LKO mice. Moreover, CD30 and CD30L were expressed preferentially by Vγ1(-)Vγ4(-) γδ T cells in naive mice. The bacteria clearance was attenuated by the impaired response of the IL-17A-producing γδ T cells and decreased infiltration of neutrophils in CD30KO or CD30LKO mice. In vivo administration of agonistic anti-CD30 monoclonal antibody restored the ability of protection against Listeria monocytogenes by enhancing Vγ1(-)Vγ4(-) γδ T cells producing IL-17A not only in wild-type but also CD30LKO mice. Taken together, it appears that CD30L/CD30 signaling plays an important role in the maintenance and activation of IL-17A-producing γδ T cells presumably bearing Vγ6 in the mucosa-associated tissues of mice.


Assuntos
Ligante CD30/metabolismo , Antígeno Ki-1/metabolismo , Listeriose/imunologia , Mucosa/imunologia , Células Th17/imunologia , Animais , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/farmacologia , Ligante CD30/genética , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Homeostase/efeitos dos fármacos , Interleucina-17/metabolismo , Antígeno Ki-1/agonistas , Antígeno Ki-1/genética , Ativação Linfocitária , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Mucosa/microbiologia , Receptores de Antígenos de Linfócitos T gama-delta/metabolismo , Células Th17/efeitos dos fármacos
2.
EMBO J ; 26(13): 3086-97, 2007 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-17557078

RESUMO

The thiol-disulfide oxidoreductase thioredoxin-1 (Trx1) is known to be secreted by leukocytes and to exhibit cytokine-like properties. Extracellular effects of Trx1 require a functional active site, suggesting a redox-based mechanism of action. However, specific cell surface proteins and pathways coupling extracellular Trx1 redox activity to cellular responses have not been identified so far. Using a mechanism-based kinetic trapping technique to identify disulfide exchange interactions on the intact surface of living lymphocytes, we found that Trx1 catalytically interacts with a single principal target protein. This target protein was identified as the tumor necrosis factor receptor superfamily member 8 (TNFRSF8/CD30). We demonstrate that the redox interaction is highly specific for both Trx1 and CD30 and that the redox state of CD30 determines its ability to engage the cognate ligand and transduce signals. Furthermore, we confirm that Trx1 affects CD30-dependent changes in lymphocyte effector function. Thus, we conclude that receptor-ligand signaling interactions can be selectively regulated by an extracellular redox catalyst.


Assuntos
Antígeno Ki-1/metabolismo , Transdução de Sinais , Tiorredoxinas/metabolismo , Anticorpos/imunologia , Catálise , Linhagem Celular , Membrana Celular/metabolismo , Dissulfetos/metabolismo , Epitopos/imunologia , Humanos , Antígeno Ki-1/agonistas , Antígeno Ki-1/classificação , Antígeno Ki-1/imunologia , Cinética , Ligantes , Linfócitos/metabolismo , Oxirredução , Ligação Proteica , Sensibilidade e Especificidade , Transdução de Sinais/efeitos dos fármacos , Tiorredoxinas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA